Register: From Proof-of-Concept to Enterprise Adoption: Scaling GenAI across Drug Development

Date: Wednesday, March 11, 2026 11am–12pm EDT
Event Location: Virtual

Generative AI pilots are now common in biopharma, but scaling these innovations enterprise-wide is where most teams stall. In this webinar hosted by Patsnap, we’ll share practical examples of how leading biopharma companies are unlocking real value across the R&D and commercialization value chain. You’ll also see how a top R&D spender broke down silos across multidisciplinary teams through the power of data, validated generative AI, and human-in-the-loop approaches that ensure responsible, ethical use.

What you’ll learn

• A practical proof-of-concept to production playbook for scaling GenAI securely across R&D, IP, and CI teams.
• High-impact use cases where AI drives measurable value, such as novelty review, competitive monitoring, and lead compound extraction.
• How to embed traceability and human review into your workflows to reduce hallucination risk and drive impactful decisions.
• A case study walkthrough covering the workflow architecture, the roles involved, and what measurable outcomes look like in an enterprise rollout.

Sam Winders

Account Director – Life Sciences

Sam is the lead representative for the healthcare and life sciences team at Patsnap. One of the organization’s longest serving employees, Sam works closely with our leading customers and the Patsnap product development team to ensure that our customers’ needs our met and that Patsnap continues to rapidly expand the technical frontier within the evolving drug discovery space.

Jennifer Smith-Parker

Director, Insights